The clinical community is closely watching this groundbreaking treatment, a combined drug targeting both GLP-1 and glucose-dependent insulinotropic polypeptide. Present studies suggest it could offer significant benefits in reducing body weight compared to current medications, potentially representing a major development in the management of excess